Evidence map›Paper›PMID 32474693›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2020

Management of stage 3B Coats disease: presentation of a combined treatment modality and long-term follow-up.

Tingyi Liang, Jie Peng, Qi Zhang, Xiuyu Zhu, Yu Xu, Peiquan Zhao

Abstract readVideo-Audio Media
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tingyi LiangDepartment of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jie PengDepartment of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Qi ZhangDepartment of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiuyu ZhuDepartment of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yu XuDepartment of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Peiquan ZhaoDepartment of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhaopeiquan@xinhuamed.com.cn.
Shanghai Jiao Tong University · CNXinHua Hospital · CN

Funding

Science and Technology Commission of Shanghai Municipality 17411952900Shanghai Shen Kang Hospital Development Center 16CR4017A
6 · The paper itself

Abstract

purposeTo present a combined treatment modality in the management of stage 3B Coats disease and to evaluate its efficacy in the long-term follow-up.

methodsThis study was a retrospective review of 29 eyes from 29 consecutive patients who had stage 3B Coats disease with total exudative retinal detachment (ERD). The combined treatment modality consisted of external drainage of subretinal fluid (SRF), followed by endolaser photocoagulation via a nonvitrectomy approach, and intravitreal ranibizumab injection. Final disease status, anatomic success, and final visual acuity were the main outcome measures.

resultsThe treated eyes initially received one session of external drainage of SRF, followed by an average of 1.4 sessions (range, 1 to 3 sessions) of endolaser photocoagulation and intravitreal ranibizumab injection. With a median follow-up period of 40 months (range, 21-81 months), all eyes demonstrated no disease progression, including 6 eyes that required vitrectomy with silicone oil tamponade due to increasing ERD after initial treatment. No enucleation was required. At the final follow-up, anatomic success with retinal reattachment and no active disease was achieved in 24 of 29 eyes (82.8%). Fibrosis was observed in 22 eyes (75.9%) with a mean onset time of 9 months (range, 5-16 months); of these, 3 and 9 eyes developed tractional retinal detachment and epiretinal membrane, respectively. In 62.1% of the eyes, the final visual acuity was only light perception or no light perception.

conclusionThe combined treatment modality presented in this study is an effective way in the management of stage 3B Coats disease with total ERD.

Indexed as

Visual AcuityAngiogenesis InhibitorsChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantIntravitreal InjectionsLaser CoagulationMaleRanibizumabRetinal TelangiectasisRetrospective StudiesSeverity of Illness IndexSlit Lamp MicroscopyAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor ACoats diseaseEndolaserExudative retinal detachmentRanibizumab

Identifiers

PMID32474693
OpenAlexW3032238490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.